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AUTOANTIGENS IN IGG4 RELATED DISEASE 
Abstract 
Immunoglobulin G4-related disease (IgG4-RD) is a newly emerging immune-mediated 
condition that can affect over a dozen organs. The systemic nature of this disease allows it to 
exhibit a plethora of diverse disorders, including malignancies, infections and also inflammatory 
diseases. This diversity is evident in the highly heterogeneous patient population, from 
pancreatic cancer patients to patients with Mikulicz’s disease. Such disorders were often 
diagnosed as isolated, single-organ diseases until the early 21st century, when IgG4-RD was 
identified by a set of histopathological characteristics seen across patient biopsies. The three 
hallmark pathological features —lymphoplasmacytic infiltration, storiform fibrosis and 
obliterative phlebitis— are vital today for a definitive diagnosis. The ability to accurately 
diagnose IgG4-RD has transformed the outlook for patients, as it is treatable, with patients 
generally responsive to immunosuppressive therapies.  
Over the past decade, we have gained great insight into the widespread immune 
dysregulation that takes place in IgG4-RD, such as elevated levels of IgG4 antibodies and the 
presence of characteristic CD4+ cytotoxic T lymphocytes in tissue lesions. However, the 
etiology of the disease is still unknown and it is unclear whether the IgG4 autoantibodies are 
drivers of the disease or a mere consequence of a robust inflammatory response.  
iii 
 
My thesis aims to address these critical questions by identifying the target antigen(s) of 
these autoantibodies. Essentially, this would provide insight into the pathogenesis in IgG4-RD 
and help elucidate possible drivers of the dysregulated immune response.  
In this paper, I discuss the twenty likely antigenic targets of IgG4 autoantibodies in 
patient serum, which were identified elegantly by the parallel analysis of translated ORF’s 
(PLATO). These antigens were then synthesized via large-scale transfection of 293F cells. 
Lastly, the specificity of patient antibodies against these recombinant proteins was then 
evaluated using ELISA, testing sera from over 100 IgG4-RD patients. 
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Figures 
Figure 1. Clinical Manifestations in IgG4-RD patients.  
A) Dacryoadenitis, caused by lacrimal gland enlargement. B) Submandibular glad enlargement. 
C) Parotid enlargement. D) Thickening of bronchovascular bundle in right lung. Picture Credit: 
Stone et. al (1) 
Figure 2. Pathological feature of IgG4-RD. Picture Credit: Stone et. al (1) 
Figure 3. TCRb repertoire of circulating expanded T effector memory cell subset in 4 IgG4-RD 
patients. Figure from Matoo et. al (2) 
Figure 4. Schematic diagram summarizing pathogenesis in IgG4-RD. Picture Credit: Shiv Pillai 
Figure 5. Heat map illustrating PLATO results. Red indicates hits with >3.5 fold enrichment 
compared to healthy controls, intense red indicates a higher number of hits (Range- 3.5x -19x). 
Figure 6. Antibody specificity against NOL3. Setting a stringent cutoff at 2 SD above the mean 
of healthy donors results in 2 % of IgG4-RD patients as positive. Interestingly, both positive 
patients exhibited midline soft tissue fibrotic lesions (i.e. 10% of this subgroup is specific to 
NOL3). 
Figure 7. Absorbance of anti-lactoferrin IgG autoantibodies. A stringent cutoff at 2 SD above 
the mean of healthy donors was set, noting 6% of IgG4-RD patients as positive. 
Figure 8. IgG subclass specificity to Lactoferrin. Patients positive in Fig. 7 were tested against 
each IgG subclass, showing the presence of anti-lactoferrin IgG1 and IgG4 antibodies. 
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Figure 9. Absorbance of anti-CA1 IgG autoantibodies. A stringent cutoff at 3 SD above the 
mean of healthy donors was set, noting 7% of IgG4-RD patients as positive. 
Figure 10. IgG subclass specificity to Carbonic Anhydrase 1. Patients positive in Fig. 9 were 
tested against each IgG subclass, showing the presence of anti-CA1 IgG2 and IgG4 antibodies. 
Figure 11. Absorbance of anti-CA2 IgG autoantibodies. A stringent cutoff at 2 SD above the 
mean of healthy donors was set, noting 5% of IgG4-RD patients as positive. 
Figure 12. IgG subclass specificity to Carbonic Anhydrase 2. Patients positive in Fig. 11 were 
tested against each IgG subclass, showing the presence of anti-CA2 IgG1, IgG3 and IgG4 
antibodies. 
Figure 13. Absorbance of anti-CA4 IgG autoantibodies. A stringent cutoff at 2 SD above the 
mean of healthy donors was set, noting 7% of IgG4-RD patients as positive. 
Figure 14. IgG subclass specificity to Carbonic Anhydrase 4. Patients positive in Fig. 13 were 
tested against each IgG subclass, showing the presence of anti-CA4 IgG1 and IgG4 antibodies. 
Figure 15. Absorbance of anti-PRSS2 IgG autoantibodies. A stringent cutoff at 2 SD above the 
mean of healthy donors was set, noting 6% of IgG4-RD patients as positive. Notably, no disease 
controls showed anti-PRSS2 IgG thus PRSS2 seems to be disease specific. 
Figure 16. IgG subclass specificity to PRSS2. Patients positive in Fig. 15 were tested against 
each IgG subclass, illustrating the presence of autoreactive IgG1 and IgG4 antibodies. 
Figure 17. Absorbance of anti-SPINK-1 IgG autoantibodies. A stringent cutoff at 2 SD above 
the mean of healthy donors was set, noting 4% of IgG4-RD patients as positive. 
vii 
 
Figure 18. IgG subclass specificity to SPINK-1. Patients positive in Fig. 17 were tested against 
each IgG subclass, showing the presence of autoreactive IgG1 and IgG2 antibodies. 
Figure 19. Chart summarizing IgG subclass specificity to autoantigens. 
Figure 20. Predominance of autoantigen specific IgG1 and IgG4 subclasses. 
Figure 21. 33% of patients were reactive to at least one of the known autoantigens in AIP. Only 
7 of 33 are AIP patients, thus these autoantigens are not limited to AIP but also present in other 
organ manifestations in IgG4-RD. 
Figure 22. Autoantigen reactivity is not limited to AIP patients. Varying organ manifestations in 
positive patients. Particularly interesting was lung involvement; no previous studies shown a 
correlation between lung involvement and increased autoantigen specificity. 
Figure 23. Fischer exact test results depicting correlation of autoantigens and organ 
manifestations in positive patients. Autoantigen reactivity correlates with manifestations of 
Lungs, Sclerosing Mediastinitis and Other ENT involvement. 
Figure 24. No lab correlations with positive patients.  
 
 
 
 
 
viii 
 
Acknowledgements 
I would like to thank Dr. Shiv Pillai of the Immunology program at Harvard Medical School who 
served as my mentor, teacher and thesis advisor. His guidance and support played an immense 
role in my success over the past two years, and he continues to inspire me today. 
I would also like to thank Dr. Cory Perugino of the Rheumatology program at Massachusetts 
General Hospital. This thesis would not have been possible without his mentorship, support and 
extensive contribution to this project.  
I am also grateful to the other members of the Pillai Lab, notably Vinay Mahajan, Ian Rosenberg, 
Hamid Mattoo and Xin Kai for helping me master various lab techniques in this project. In 
addition, I would like to acknowledge the Elledge lab for their key role in PLATO and Grant 
Weaver at the Ragon Institute of MGH, MIT and Harvard for his guidance in protein production 
and purification.  
Finally, I must express my profound gratitude to my parents and sister who provided the 
unwavering support and motivation that I need to thrive in all my years of study, and in 
completing my thesis and achieving a Masters of Medical Sciences in Immunology from 
Harvard Medical School. 
 
This work was conducted with support from Students in the Master of Medical Sciences in 
Immunology program of Harvard Medical School. The content is solely the responsibility of the 
authors and does not necessarily represent the official views of Harvard University and its 
affiliated academic health care centers. 
Chapter One 
Background 
Immunoglobulin G4-related disease (IgG4-RD) is an emerging systemic immune-
mediated condition that exhibits a wide variety of disorders. It is a multi-organ condition that can 
affect up to a dozen organs to resemble malignancies, infectious and inflammatory diseases, such 
as pancreatic cancer, autoimmune pancreatitis and Mikulicz’s disease. These disorders were 
often diagnosed as isolated, single-organ diseases until the early 21st century, when IgG4-RD 
was identified by a number of histopathological characteristics seen across patient biopsies.2 The 
three hallmark pathological features —lymphoplasmacytic infiltration, storiform fibrosis and 
obliterative phlebitis— remain key today for a definitive diagnosis. This has proved crucial in 
transforming the outlook for patients, as IgG4-RD is treatable, with patients generally responsive 
to immunosuppressive therapies.  
 
Epidemiology 
Over the past decade, we have gained great insight into the clinical and 
pathophysiological manifestations of IgG4-RD. However, the epidemiological data continues to 
remain scarce due to the relatively young age of the disease as well as the difficulty in 
recognition. Unlike many classic autoimmune disorders, IgG4-RD has a predilection for men, 
with 3.5 times as many male patients than female. Although there are no known familial cases of 
IgG4-RD, genetic studies have shown a bias in major histocompatibility complex class II in men 
of Asian descent3. Collecting accurate epidemiological data will only be possible once awareness 
of IgG4-RD and its diagnosis increases amongst practitioners. 
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 Clinical Manifestations & Organ Involvement 
IgG4-RD patients present with symptoms and organ dysfunction for extended periods of time 
prior to diagnosis. Common symptoms include fatigue, musculoskeletal symptoms or significant 
weight loss (5-10 kilograms)3. Disease progression is rarely continuous, with patients frequently 
showing spontaneous, but temporary improvements. IgG4-RD is suspected either when disease 
recurs in a particular organ or if additional organs are affected. Discussed below are a few of the 
extensive organs involved in IgG4-RD. 
Head and Neck 
IgG4-RD patients encompass a 
wide variety of clinical 
manifestations in the head and neck 
regions. In fact, multiple diseases, 
such as Kuttner’s tumor and 
Mikulicz disease, are now 
recognized as classic IgG4-related 
conditions. Identified over 100 
years ago, Mikulicz disease entails 
enlargement of the parotid, submandibular and lacrimal glands— all common findings in IgG4-
RD. 
Patients further present with a wide range of orbital and periorbital lesions, ranging from 
tumefactive lesions to enlarged lacrimal-glands (dacryoadenitis). These lesions are extensive and 
Figure 1. Clinical Manifestations in IgG4-RD patients.  
A) Dacryoadenitis, caused by lacrimal gland enlargement. B) 
Submandibular glad enlargement. C) Parotid enlargement. D) 
Thickening of bronchovascular bundle in right lung. Picture Credit: 
Kamisawa et. al2 
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may infiltrate along the trigeminal nerve or into the cavernous sinus, and are thus misidentified 
as malignancies.  
Prominent allergic features are also evident in a number of patients, specifically in the ears, nose 
and throat.  These patients tend to have a history of allergies long before an IgG4-RD diagnosis, 
and sometimes have ten times the upper limit of IgE levels in serum3. Further, diffuse 
inflammation is seen in the pharynx, hypopharynx and trachea. Mass lesions in the sinuses and 
destructive lesions in the middle ear and facial bones have also been reported. 
 
Chest  
The lungs exhibit the greatest diversity of clinical presentations, which can be classified into four 
distinct syndromes: inflammatory pseudotumor, central airway disease, localized/diffuse 
interstitial pneumonia and pleuritis. Clinically, patients present with typical symptoms such as 
cough, dyspnea and chest discomfort. However, the radiologic manifestations in patients are 
highly prominent, including pulmonary nodules, pleural thickening, ground-glass opacities and 
interstitial lung disease. A characteristic lesion of IgG4-RD, the bronchovascular bundle, is also 
identified radiologically through a CT scan2. 
 
The pathological differences in the lung and other affected organs contrast strikingly. Lungs tend 
to exhibit obliterative arteritis, which is rarely evident in other organs (as well as the more 
common obliterative phlebitis). Further, lungs are more likely to have neutrophilic infiltrate, due 
to their interface with the external environment.  
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Pancreas 
The pancreas displays the typical histopathological features of IgG4-RD in patients with type 1 
autoimmune pancreatitis (AIP). This form of AIP is more prevalent worldwide and is associated 
with IgG4, unlike type 2 AIP, which is unrelated to IgG4 and rather features neutrophillic 
infiltration into the epithelium of the pancreatic duct. 
Interestingly, the pancreas was one of the first organs to be associated with elevated serum IgG4 
levels. However, evaluation of additional criteria including pancreatic histology, imaging and 
glucocorticoid responsiveness is necessary to differentiate autoimmune pancreatitis from 
pancreatic cancer. This is vital, as many patients have undergone unnecessary surgical 
procedures due to presumed pancreatic cancer. Indeed, there are several reported cases of 
pancreatic cancer in patients with AIP.  
 
Other organs 
The systemic nature of IgG4-RD adds much diversity to its clinical presentations; we are now 
seeing involvement of organs previously thought to be out of the IgG4-RD spectrum. For 
example, although brain involvement is rare, IgG4-RD is the most common causes of 
hypertrophic pachymeningitis. Similarly, skin manifestations such as erythematous papules and 
hyperpigmented lesions have been reported in the head and neck areas.  
These features display the complexities and multi-faceted nature of IgG4-RD and suggest a 
complicated disease pathogenesis consisting of multiple pathways. 
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Histopathology of IgG4-Related disease 
The systemic nature of IgG4-RD has prevented the recognition of an underlying condition for 
centuries and its mimicry of conditions, ranging from inflammatory disorders to malignancies, 
has further helped in its disguise. However, the 
identification of common histopathological and 
immunohistochemical features linked disorders 
once thought to be single-organ conditions. Today, 
an accurate, and definitive diagnosis can be 
achieved through a histopathological interpretation. 
This contrasts most autoimmune conditions that are 
diagnosed through a serological evaluation, such as 
rheumatoid arthritis. A tissue biopsy is the gold 
standard for a diagnosis as it reveals the three 
central features of IgG4-RD2: 
Storiform Fibrosis 
All IgG4-RD patients exhibit some extent of 
storiform fibrosis (figure 2B). Patient tissues display an abnormal pattern of radially arranged 
collagen fibers, which is thought to be driven by macrophages and activated fibroblasts. This 
form of fibrosis is characteristic to IgG4-RD and is rarely seen in other inflammatory diseases. 
Despite its characteristic appearance, it typically appears in patches and thus can often be 
overlooked.   
Figure 2. Pathological feature of IgG4-RD.  
Picture Credit: Kamisawa et. al 2 
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Obliterative Vascular Disease 
Obliterative vascular disease is the partial of complete occlusion of blood vessels by 
inflammatory infiltrate comprised of lymphocytes and plasma cells. Veins are predominantly 
affected in IgG4-RD, with patients exhibiting extensive obliterative phlebitis (figure 2C). These 
veins commonly form an inflammatory nodule next to a patent artery, which is easily identified 
from a tissue biopsy (figure 2H). Although rare in most organs, arteries can also be affected, and 
is seen most commonly in the lungs. Both obliterative phlebitis and obliterative arteritis are 
unique to IgG4-RD, and thus carry immense diagnostic value.   
 
Lymphoplasmacytic Infiltrate 
IgG4-RD can be distinguished by the abnormally high IgG4-positive plasma cells in patient 
tissues. Although IgG4 concentrations in patient sera are not always elevated, they are notably 
high across patient lesions. This hallmark alone is not sufficient to determine a definitive 
diagnosis, as IgG4-positive cells are present in inflammatory and neoplastic disorders such as 
granulomatosis with polyangitis, rheumatoid arthritis, etc. Thus, additional criteria need to be 
assessed in order to confirm disease diagnosis, such as the ratio of IgG4:IgG+ plasma cells 
(Figure 2F).. Also seen elevated in lesions are plasma cells expressing other immunoglobulins 
and subtypes, albeit in concentrations much lower than IgG4-bearing plasma cells.  
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Pathophysiology 
Role of Immunoglobulin G4 
Despite the elevated tissue, and occasionally serum, concentrations of IgG4 it is unlikely that this 
immunoglobulin is the driver of pathogenesis. Unlike the other subsets of IgG, IgG4 is unable to 
fix complement as it undergoes a process called Fab arm exchange. Here, the heavy chains 
dissociate into two hemi-molecules, which then associate with other hemi-molecules. Thus, IgG4 
antibodies are functionally monovalent and unable to bind to activating FcγR. Rather, they are 
thought to be anti-inflammatory as they bind well to inhibitory FcγR. Although this has been the 
conventional thinking, recent literature illustrates the pathogenicity of serum IgG4 (from patients 
with AIP) on mice pancreas and salivary glands.  
 
Current hypothesis 
The immune response seen in IgG4-RD is complex, with inflammatory lesions infiltrated with 
high levels of characteristic lymphocytes (IgG4+ plasmablasts, CD4+ Cytotoxic T-cells) as well 
as innate immune cells (macrophages, eosinophils, fibroblasts, and myofibroblasts). There are 
two processes that are thought to result in the clinical manifestations of IgG4-RD.  
The first implicates the role of T helper cells in disease pathogenesis, which seems plausible due 
to their high concentration and localization to patient lesions. These T helper cells are polarized 
in response to an unknown trigger such as commensal microbes, environmental allergens, 
infectious pathogens or even tissue damage (whether the Th1 or Th2 pathway is activated 
remains disputed). Once polarized, these T helper cells produce a robust inflammatory cytokine 
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milieu that includes IFN-g, IL-4, IL-5 and IL-13. Further, T-follicular helper cells produce IL-4 
and IL-10 to drive preferential class switching of autoreactive B cells to IgG4 and IgE, and thus 
induce the differentiation and expansion of IgG4+ plasma cells3.  
 
The cytokine milieu further shapes IgG4-RD into a fibro-inflammatory disorder by generating 
profibrotic macrophages, while Interleukins 5 and 13 and TGF-β recruit eosinophils and activate 
fibroblasts. Both the macrophages and fibroblasts then create the dense storiform pattern of 
fibrosis that is characteristic of IgG4-RD3.  
 
The second underlying process is thought to be a feedback negative regulatory process involving 
autoreactive plasmablasts that present self-antigen to autoreactive T cells. This leads to a cycle of 
T-B cell collaboration and increasing numbers of high-affinity autoreactive B cell clones, finally 
resulting in the fibroinflammatory immune response seen in IgG4-RD patients2. 
 
Pathogenesis 
Although IgG4-RD is a relatively new entity, recent research has elucidated key players in its 
pathogenesis. Recent publications from the Pillai Lab have identified two characteristic cell 
types that were largely increased in active IgG4-RD patients. 
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The first, CD4+ cytotoxic T 
lymphocytes, were clonally 
expanded and infiltrated 
affected tissue sites. The 
clonality of these expanded 
cells was identified by next 
generation sequencing of 
the T cell receptor β chain, 
revealing a predominance 
of SLAMF7, granzymeA, 
IL-1β and TGF-β 
expressing CD4+ CTL’s. 1 
 
 
The second lymphocyte population of CD19+ CD27+ CD20- CD38hi cells is specifically 
interesting, as they are a hallmark of active IgG4-RD. These clonally expanded plasmablasts 
undergo enhanced somatic hypermutation, express high levels of MHC II molecules and are 
IgG4+. Interestingly, Mattoo et. al4 further illustrated that these plasmablasts secrete self-reactive 
IgG4 autoantibodies.  
 
Figure 3. TCRb repertoire of circulating expanded T effector 
memory cell subset in 4 IgG4-RD patients. Figure from 
Matoo et. al1 
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Patients treated with B cell depletion therapy using Rituximab, an anti-CD20 monoclonal 
antibody, showed a striking clinical improvement. Most importantly, patients exhibited a clear 
correlation between clinical improvement and decreased CD4+ CTL’s (and of course B-cell 
depletion)5. This correlation, as well as the high MHC II expression on these self-reactive 
plasmablasts, alludes to their role as antigen presenting cells to CD4+ CTL’s. Whether they 
present antigen to trigger initial disease or in the later stages to simply reactivate CD4+ CTL’s 
remains unknown. However, the key question that will help elucidate diseases pathogenesis is: 
What autoantigens are these self-reactive plasmablasts presenting?   
 
I sought to approach this challenge from multiple directions. First, I would identify the primary 
autoantigen using an elegant technique known as PLATO. In addition, I would also study 
autoantigens that had previously been identified in autoimmune pancreatitis (AIP)—now 
considered a manifestation of IgG4-RD. These autoantigens had not been previously looked at in 
the context of IgG4-RD, thus studying them in a heterogeneous IgG4-RD cohort would 
potentially provide great insight. 
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Figure 4. Schematic diagram summarizing pathogenesis in IgG4-RD. Picture Credit: 
Shiv Pillai 
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Chapter Two 
 
Data: Short Introduction 
Studies over the past decade have provided great insight into the immune dysregulation in IgG4-
RD, particularly the identification two characteristic lymphocytes that are clonally expanded in 
active patients:  CD19+ CD27+ CD20- CD38hi plasmablasts1 and CD4+ cytotoxic T 
lymphocytes4. We believe these plasmablasts are presenting antigens to CD4+ CTL’s, 
identifying the specific autoantigens is key in elucidating disease pathogenesis and hopefully, the 
etiology of IgG4-RD. 
 
Experiment Outline 
Here, we used an elegant technique, PLATO, to identify immune targets of serum antibodies 
from patients with active IgG4-RD. We sought to validate these PLATO interactions after 
determining the top target autoantigens, and cloned plasmids with genes encoding the top twenty 
proteins. These plasmids were transfected into suspended 293F cells to produce large-scale 
recombinant proteins. After two days, cells were lysed and the protein of interest was purified 
using an affinity column. Lastly, these recombinant autoantigens were used to test specificity of 
serum autoantibodies using an indirect ELISA assay.  
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Materials and Methods 
Parallel analysis of translated Open Reading Frames (PLATO) 
First published in 2013, PLATO is an elegant in vitro technique designed by the Stephen Elledge 
to discover protein-protein interactions in an unbiased manner6. First, PLATO transcribes and 
translates a library of open reading frames (ORFs) in vitro. Then using Ribosomal Display, ORF-
encoded proteins and mRNA are then linked into a complex— which remains intact due a 
mutated stop codon— and exposed to surface-immobilized ‘bait’ molecules, such as antibodies. 
Finally, bound mRNA is eluted, reverse transcribed and sequenced for protein identification. 
This experimental protocol can identify novel proteins for various uses, such as drug target 
determination, protein-protein interaction and also for identifying autoantibody antigen. PLATO 
has several advantages over other screens, namely library size and cost. Being an in vitro 
technique further provides advantages such as the ability to synthesize proteins toxic to cells, but 
can also serve as a limitation, as in vitro proteins lack the natural conformation and post-
translational modifications seen in vivo proteins. 
 
PLATO overview: 
The Elledge Lab at Harvard Medical School performed PLATO and provided us with the top 
protein ‘hits’ shared in Figure 5. However, a review of the experimental design from protocol is 
shared below6: 
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1- Preparation of the Ribosomal Display ORFeome library 
PLATO requires a library of ORF’s as input, thus we utilized the human ORFeome 
collection, which was constructed via PCR cloning from cDNA libraries into the 
Gateway entry vector system. Importantly, native stop codons were mutated into coding 
sequences to allow addition of the C terminal fusion tags to expressed polypeptides (Zhu 
et. al 2013). To avoid representational bias such as lower recombination and 
amplification efficiencies in longer transcripts, the ORFeome entry vector library was 
split into 18 subpools and subcloned into the pRD-DEST expression vector. Expression 
plasmids were then PCR-amplified, resulting in DNA templates ready for in vitro 
transcription. 
 
2- ‘Panning’: Library enrichment on surface-immobilized bait 
Ribosomal display (RD) was then employed to link the ORF-derived mRNA molecules 
to their encoding proteins, and the complex of mRNA-protein-ribosomes was incubated 
with serum autoantibodies to undergo ‘panning’. These antibodies were immobilized as 
they were covalently bound to magnetic protein A/G beads. 
 
3- Conversion of recovered mRNA into 3′ tag DNA libraries for deep sequencing or qPCR 
analysis. 
The enriched mRNA library is then eluted, fragmented and reverse transcribed. The 3’ 
end of the resulting cDNA is then polyadenylated prior to deep DNA sequencing and 
analysis. We further subjected the enriched mRNA library to ORF-specific qPCR to 
validate PLATO interactions. 
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Gateway Cloning 
We then sought to synthesize the top twenty proteins identified by PLATO and test them against 
patient serum. In order to do so, we purchased Gateway vectors expressing genes that encoded 
these proteins. We then cloned our genes of interest into the destination vector pHWF using 
Invitrogen™ Gateway™ recombination cloning. 
 
Subjects 
Sera from 100 IgG4-RD patients were studied and compared to 40 healthy donors. In addition, a 
disease control cohort consisting of 6 Systemic lupus erythematosus (SLE), 9 Anti-neutrophil 
cytoplasmic antibody-associated vasculitis (AAV) and 15 Rheumatoid Arthritis (RA) patients 
was added to evaluate disease specificity. We used a heterogeneous cohort of IgG4-RD patients 
who expressed a range of clinical manifestations. Results were later analyzed based on patient 
labs and organ manifestations. 
 
Cell Culture and Transfection 
We initially cultured and transfected Human Embryonic Kidney (HEK) 293T cells to express our 
proteins of interest. However, we later optimized our protocol to incorporate large-scale protein 
production and used suspended 293 Freestyle cells (ThermoFisher catalog no. R79007). These 
cells were cultured at a concentration of 0.5 x 10^6 cells/ml in 250ml of Freestyle medium 
(ThermoFisher catalog no. 12338018) and placed in an orbital shaker incubator at 37 °C, 120 
rpm, and 5% CO2 for 24 hours. Cells were then co-transfected with protein encoding plasmids 
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and PEI and placed back in the orbital shaker incubator for an additional 48 hours. Finally, the 
transfected cells were centrifuged for 5 minutes at 3,000x, and the resulting pellets were stored at 
-80°C (if not immediately lysed). 
 
Cell lysis and protein purification 
The pellets obtained from centrifugation were then lysed using with our lysis buffer (100 mM 
potassium acetate, 50 mM Tris pH 7.5, 1% NP-40, protease inhibitors). We further ensured 
complete cell lysis by sonicating cells for 5 cycles (15 seconds on and off, at 10 Hz amplitude). 
Cell lysates were then spun at 3,000x g at 4°C for 25 minutes to remove cell debris; the 
supernatant was stored for purification. 
 
Proteins were then purified using affinity chromatography, as our desired proteins were all 
FLAG tagged. Supernatant was incubated overnight at 4C with anti-FLAG affinity beads (Sigma 
Aldrich cat. no. A2220), and then run through a column. Proteins were then eluted via 
competitive binding, by running 5 column volumes of 100 μg/ml of FLAG peptide (Sigma 
Aldrich cat. no. F3290) 
All samples were run on a 10% SDS-PAGE gel followed by an anti-FLAG western blot to 
confirm we isolated our protein of interest.  
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ELISA (Enzyme Linked Immunosorbent Assay) 
Nunc-Immuno™ MicroWell™ 96 well solid plates (Sigma Aldrich cat. no. M9410) were coated 
with 100μl of 5μg/ml antigen and incubated overnight at 4°C. Wells were then washed 4 times 
with phosphate buffered saline containing 0.05% Tween-20 (PBS-T) and then incubated 
overnight at 4°C with 300μl of 5% bovine serum albumin in PBS-Tween. After four washes of 
PBS-T, patient serum (1:100) was added to wells and left to incubate at room temperature for 2 
hours. Wells were washed with PBS-T four times and then incubated with secondary antibody 
(anti-IgG conjugated with horseradish peroxidase enzyme (Sigma Aldrich cat. no. A8792) for 
one hour at room temperature. After four more washes of PBS-T, 100μl of 0.4mg/ml OPD 
substrate (Sigma Aldrich cat. no. P9187) was added to wells and left to incubate at room 
temperature for 15 minutes. The reaction was then stopped using 100μl of 3M sulfuric acid 
solution and absorbance was determined at 492nm. All wells were normalized to blank wells 
(containing only PBS), and absorbance due to antigen was calculated by subtracting absorbance 
of control wells (with patient sera but no antigen) from antigen-coated wells. All samples were 
performed in triplicates.  
 
Statistical Analysis 
The Fischers exact test was used to evaluate differences between antibody responses in IgG4-RD 
patients compared to those in the control group (healthy donors), and also to analyze correlations 
between specific autoantigens and organ involvement. Statistical difference was defined as p 
<0.05.  
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RESULTS 
  
Figure 5. Heat map illustrating PLATO results. Red indicates hits with >3.5 fold enrichment 
compared to healthy controls, intense red indicates a higher number of hits (Range- 3.5x -19x).  
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PLATO: Nucleolar Protein 3 (NOL3) 
 
Figure 6. Antibody specificity against NOL3. Setting a stringent cutoff at 2 SD above the mean 
of healthy donors results in 2 % of IgG4-RD patients as positive. Interestingly, both positive 
patients exhibited midline soft tissue fibrotic lesions (i.e. 10% of this subgroup is specific to 
NOL3). 
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Autoantigens identified in autoimmune diseases other than IgG4-RD 
 
1. Lactoferrin 
 
 
Figure 7. Absorbance of anti-lactoferrin IgG autoantibodies. A stringent cutoff at 2 SD above 
the mean of healthy donors was set, noting 6% of IgG4-RD patients as positive. 
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Figure 8. IgG subclass specificity to Lactoferrin. Patients positive in Fig. 7 were tested against 
each IgG subclass, showing the presence of anti-lactoferrin IgG1 and IgG4 antibodies. 
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2. Carbonic Anhydrase 1 
 
Figure 9. Absorbance of anti-CA1 IgG autoantibodies. A stringent cutoff at 3 SD above the 
mean of healthy donors was set, noting 7% of IgG4-RD patients as positive. 
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Figure 10. IgG subclass specificity to Carbonic Anhydrase 1. Patients positive in Fig. 9 were 
tested against each IgG subclass, showing the presence of anti-CA1 IgG2 and IgG4 antibodies. 
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3. Carbonic Anhydrase 2 
 
Figure 11. Absorbance of anti-CA2 IgG autoantibodies. A stringent cutoff at 2 SD above the 
mean of healthy donors was set, noting 5% of IgG4-RD patients as positive. 
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Figure 12. IgG subclass specificity to Carbonic Anhydrase 2. Patients positive in Fig. 11 were 
tested against each IgG subclass, showing the presence of anti-CA2 IgG1, IgG3 and IgG4 
antibodies. 
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4. Carbonic Anhydrase 4 
 
Figure 13. Absorbance of anti-CA4 IgG autoantibodies. A stringent cutoff at 2 SD above the 
mean of healthy donors was set, noting 7% of IgG4-RD patients as positive. 
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Figure 14. IgG subclass specificity to Carbonic Anhydrase 4. Patients positive in Fig. 13 were 
tested against each IgG subclass, showing the presence of anti-CA4 IgG1 and IgG4 antibodies. 
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Pancreatic Autoantigens 
5. Proteinase Serine 2 (PRSS2) 
 
Figure 15. Absorbance of anti-PRSS2 IgG autoantibodies. A stringent cutoff at 2 SD above the 
mean of healthy donors was set, noting 6% of IgG4-RD patients as positive. Notably, no disease 
controls showed anti-PRSS2 IgG thus PRSS2 seems to be disease specific. 
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Figure 16. IgG subclass specificity to PRSS2. Patients positive in Fig. 15 were tested against 
each IgG subclass, illustrating the presence of autoreactive IgG1 and IgG4 antibodies. 
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6. Pancreatic secretory trypsin inhibitor (SPINK-1) 
 
Figure 17. Absorbance of anti-SPINK-1 IgG autoantibodies. A stringent cutoff at 2 SD above 
the mean of healthy donors was set, noting 4% of IgG4-RD patients as positive. 
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Figure 18. IgG subclass specificity to SPINK-1. Patients positive in Fig. 17 were tested against 
each IgG subclass, showing the presence of autoreactive IgG1 and IgG2 antibodies. 
 
Figure 19. Chart summarizing IgG subclass specificity to autoantigens. 
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Figure 20. Predominance of autoantigen specific IgG1 and IgG4 subclasses. 
 
 
Figure 21. 33% of patients were reactive to at least one of the known autoantigens in AIP. Only 
7 of 33 are AIP patients, thus these autoantigens are not limited to AIP but also present in other 
organ manifestations in IgG4-RD. 
IgG4-RD patients reactive to known AIP 
autoantigens
Reactive Unreactive
33 
 
 
Figure 22. Autoantigen reactivity is not limited to AIP patients. Varying organ manifestations in 
positive patients. Particularly interesting was lung involvement; no previous studies shown a 
correlation between lung involvement and increased autoantigen specificity. 
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Figure 23. Fischer exact test results depicting correlation of autoantigens and organ 
manifestations in positive patients. Autoantigen reactivity correlates with manifestations of 
Lungs, Sclerosing Mediastinitis and Other ENT involvement. 
 
 
 
Figure 24. No lab correlations with positive patients.  
 
  
Variable (mean) Auto-Ab Positive (n=26) Auto-Ab Negative (n=74) p-value
Total IgG 2,035 1,823 0.56
IgG1 1,045 917 0.36
IgG2 665 695 0.89
IgG3 83 162.8 0.14
IgG4 548 534 0.89
IgE 342 505 0.41
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Brief Discussion 
Interestingly, our ELISA data revealed the presence of multiple autoantigen specific IgG 
subclasses in positive patients, as well as the predominance of IgG1 and IgG4. The elevated 
subclasses seen in positive patients correlated with serum subclass elevations evident in lab 
reports (data not shown). These findings may allude to a possibility of interplay between the IgG 
subclasses, i.e. IgG1 may be driving disease pathogenesis while the non-inflammatory IgG4 
molecule may be clonally expanded to suppress the inflammatory response.  
 
Previous literature on autoantigens in diseases such as SLE and RA indicates the loss of 
tolerance, with many autoimmune conditions sharing the same autoantigens7. This can be seen in 
our ELISA results, where disease controls also exhibit autoreactive IgG to antigens such as 
Carbonic Anhydrases 2 and 4. However, other autoantigens tested seemed to be more specific to 
IgG4-RD, such as Carbonic Anhydrase 1, PRSS2 and SPINK-1.  
 
Limitations 
Although we successfully identified patient specificity to the above autoantigens, our experiment 
had some limitations. We synthesized our recombinant PLATO proteins and verified their 
presence via western blot but were unable to detect them on a Coomassie stain. This meant we 
had not synthesized a sufficient yield, which may have been due to an unsuitable plasmid or 
early degradation of our desired protein. Although this hindered our ability to test all PLATO 
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proteins, we still analyzed specificity of one PLATO protein, NOL3, after purchasing it 
commercially. 
 
Furthermore, we are currently utilizing an alternative, highly sensitive antibody-profiling assay –
Luciferase Immunoprecipitation System (LIPS) to detect specificity to PLATO proteins8. We are 
also cloning our genes of interest into a new plasmid encoding a secretory signal, to optimize 
protein production and increase protein yield.  
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Discussion and Perspectives 
Antigen presentation plays a central role in most, if not all, autoimmune diseases. It is no 
coincidence that the major histocompatibility complex gene is a major disease susceptibility 
locus in numerous autoimmune conditions such as Multiple sclerosis, Rheumatoid Arthritis, and 
Type-1 diabetes7. A growing number of studies on the peptide-MHC-TCR interaction in these 
diseases have identified a wide range of autoantigens, some characteristic of a particular disease, 
while others are shared across many diseases9.  
Further, it is also becoming increasingly evident that antibodies play a vital role in the 
pathogenesis of such diseases, from tissue injury to exacerbating systemic inflammation7. The 
role of B cells in autoimmunity has been studied in many diseases such as MS and now in IgG4-
RD; these B cells are believed to play numerous pathogenic roles such as secreting 
autoantibodies, secreting pro-inflammatory cytokines or even activating a cell-mediated response 
by serving as antigen processing cells.  The pathogenicity of these antibodies makes it imperative 
to identify their target antigens, however the increased reactivity to self-antigens as well as 
phenomenon like epitope spreading add to the complexity of identifying a ‘trigger antigen’. 
Numerous hypotheses attempt to explain this influx of autoantigens in autoimmunity, from 
molecular mimicry by pathogens to release of intracellular antigens due to frequent cell death.  
In terms of IgG4-RD, very little is known. Such autoantigens have been described in 
relevant conditions like type 1 autoimmune pancreatitis (AIP), where patients were found to 
express putative autoantibodies against carbonic anhydrases10, lactoferrin11, and several 
pancreatic and salivary antigens12. However, these autoantigens have not been studied in the 
context of IgG4-RD; identifying such antigens and their correlation to organ manifestations can 
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provide great insight into the pathogenesis underlying IgG4-RD. Importantly, it can also provide 
possible therapeutic targets to halt the robust autoimmune response in patients. 
 Our experimental findings revealed some interesting correlations. Firstly, we illustrated 
that the autoantigens previously identified in AIP were seen across our heterogenous IgG4-RD 
cohort (Figure 21). In fact, only 7 of our 33 patients positive for autoantibodies were AIP, thus 
these autoantigens are not limited to AIP but also present in other organ manifestations in IgG4-
RD. (Figure 22).  
This led us to question if reactivity to autoantigens correlated with a patient’s organ 
involvement. To analyze this statistically, we used a Fischers exact test and were surprised to see 
a significant correlation between involvement of lungs, other ENT and sclerosing mediastinitis 
and whether patients had autoreactive antibodies. This was noteworthy, especially since 4 out of 
the 6 patients positive for PRSS2 had lung manifestations. It may be interesting to elucidate the 
pathogenesis in these patients and if it differs from other IgG4-RD patients, i.e. are they more 
prone to a loss of tolerance?  
 Another key finding in our project was the presence of multiple IgG subclasses specific 
to each autoantigen. This seemed striking since it alluded to the idea of interplay between IgG 
subclasses and highlighted the complexity of the immune response. It further raises questions 
such as why are IgG1 and IgG4 predominantly expressed? Are their functions synchronous or 
antagonistic? Analyzing the differences in IgG subclasses in context of different autoantigens 
may provide us with a better understanding of the role of B cells in IgG4-RD.  
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Future Directions 
Due to the limitations discussed in the results sections, we are incorporating a highly 
sensitive, antibody-profiling assay— Luciferase Immunoprecipitation System (LIPS)8, 13. This 
will allow us to test patient antibody specificity against the 20 PLATO proteins. 
 In addition, we will simultaneously be synthesizing recombinant monoclonal 
immunoglobulins (heavy and light chains) from patients with active IgG4-RD. These 
immunoglobulins will then be exposed to whole cell lysate and their antigenic targets will be 
identified.  
 Finally, we will confirm if the antigen is sufficient to cause T-cell proliferation, using a 
cytotoxic T cell proliferation assay containing CD4+ cytotoxic T lymphocytes, antigen, and 
peripheral blood mononuclear cells. 
 
Conclusion 
 Our results identified twenty potential antigenic targets in IgG4-RD and studied 
autoantigens that were seen in several autoimmune disorders but had not been analyzed in the 
context of IgG4-RD. Our results, namely the presence of autoantigen specific antibodies, suggest 
that there may indeed be a breach in tolerance against self-antigens, consequently producing 
autoantibodies which mediate pathogenic effector functions and instigation of clinical 
symptoms14. However, our results brought up numerous questions regarding heterogeneity 
between patients, in terms of autoantigen reactivity as well as autoreactivity of varying IgG 
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subclasses. I hope to be answer these questions through future experiments and gain insight into 
the pathogenic mechanism in IgG4-RD. 
Although it has been a little over a decade since the recognition of IgG4-RD, we have 
learnt an immense amount about the disease, from an accurate diagnosis to treating with 
Rituximab. Nevertheless, determining the primary autoantigen remains a crucial step in 
unfolding the pathogenesis underlying IgG4-RD. Gaining a through understanding of disease 
etiology may currently seem like an enormous challenge, but it is one that we must overcome to 
develop new and effective therapeutics for patients.  
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